News
-
FDA Approves Remicade To Treat Ulcerative Colitis In Children 6 Years And Older
9/30/2011
The U.S. Food and Drug Administration recently approved Remicade (infliximab) to treat moderately to severely active ulcerative colitis (UC) in children 6 years and older who have had inadequate response to conventional therapy.
-
BARDA Funds Development Of Five Drugs To Protect Against Radiation
9/30/2011
The development of five new drugs to treat injuries associated with acute radiation syndrome will move forward under contracts awarded by the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA).
-
Cempra Announces Comparable Efficacy Of Oral Solithromycin (CEM-101) Compared With Levofloxacin In Phase II Clinical Trial In Patients With Community-Acquired Bacterial Pneumonia (CABP)
9/20/2011
Cempra Pharmaceuticals today announced results from its Phase II clinical trial investigating the efficacy, safety and tolerability of oral administration of our fourth generation macrolide, solithromycin (CEM-101), a fluoroketolide antibiotic, in comparison with oral levofloxacin for the treatment of community-acquired bacterial pneumonia (CABP).
-
Olympus Launches Fall 2011 Seminar Series On Whole Slide Image Analysis And Stereology
9/13/2011
Olympus has announced the schedule for its Fall 2011 Whole Slide Image Analysis and Stereology Seminar Series. The Spring 2011 seminar series was attended by hundreds of participants nationwide.
-
SDC Introduces Dr. Dale W. Usner As Its New Vice President Of Biostatistics
9/13/2011
Statistics & Data Corporation (SDC) announced today that Dale W. Usner, Ph.D. joined its team as the Vice President of Biostatistics.
-
AstraZeneca Announces Top-Line Results From SATURN Study
9/6/2011
AstraZeneca today announced top-line results from SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN). SATURN was designed to measure the impact of CRESTOR (rosuvastatin) 40 mg and atorvastatin 80 mg on the progression of atherosclerosis in high risk patients.
-
Top-Line Results From Pivotal Trial Of Dermagraft For Venous Leg Ulcers
8/25/2011
Shire plc, the global specialty biopharmaceutical company, recently announced that Advanced BioHealing (ABH), its regenerative medicine business, has concluded its phase three pivotal trial of Dermagraft in subjects with venous leg ulcers.
-
DigiPath Licenses Olympus Digital Pathology Patents
8/18/2011
DigiPath, Inc., a provider of affordable, innovative and reliable digital pathology solutions, and Olympus America Inc., a precision technology leader designing and delivering innovative solutions in life science imaging and other product areas, have entered into a nonexclusive worldwide agreement allowing DigiPath and its OEM partners to access an extensive portfolio of Olympus patents in the field of virtual microscopy and digital pathology.
-
Aeterna Zentaris Announces Completion Of Patient Recruitment For Phase 3 Trial With Perifosine In Refractory Advanced Colorectal Cancer
8/10/2011
Aeterna Zentaris Inc (the "Company") recently announced the completion of patient recruitment for the ongoing Phase 3 trial with perifosine in refractory advanced colorectal cancer.
-
BARDA Supports Development Of New Drugs To Treat Radiation Injury
8/2/2011
The first two contracts for advanced development of drugs to treat gastrointestinal (GI) tract injuries associated with acute radiation syndrome were awarded recently by the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA).
This website uses cookies to ensure you get the best experience on our website. Learn more